Blog

Why Evrima Chicago is Pioneering A11y, Cybersec & Reputation Management for an Aging Digital World

NAPERVILLE, IL / ACCESS Newswire / June 18, 2025 / In a world increasingly dependent on digital access – where aging populations are growing alongside rising cyber threats – Evrima Chicago has positioned itself as a vanguard. Its mission is clear: protect, empower, and elevate older adults and ultra-visible individuals navigating a chaotic digital landscape.

Whether it’s defending a Nobel Peace Prize laureate from impersonation scams, equipping a forensic psychiatrist with secure communications, or ensuring a Pentagon official’s reputation remains intact through a hostile media cycle – Evrima operates at the cutting edge of accessibility, cybersecurity, and elite reputation management.

The Gray Net: Where Aging Meets Digital Vulnerability

By 2050, the global senior population is projected to exceed 2 billion, and the so-called “silver economy” is expected to grow beyond $15 trillion. Despite this staggering market, mainstream tech and cybersecurity firms still under-serve older adults.

That’s where Evrima Chicago steps in. Based in Naperville, Illinois, this firm isn’t just building tools – it’s designing dignity. With assistive technology spanning screen readers, voice-command systems, and immersive virtual reality experiences, Evrima ensures digital inclusion for seniors and individuals with special needs. Accessibility – or A11y – isn’t a feature. It’s their foundation.

When Cybercrime Crosses Generational Lines

Older adults lost more than $3.4 billion to cybercrime in 2023, with the most at-risk individuals including not just everyday retirees – but aging professionals such as lawyers, doctors, and former intelligence officers. These individuals require a new kind of protection: stealth-class cyber defense.

Evrima combats these threats with military-grade protocols, behavioral threat modeling, and deep reputational shielding. These tools protect not only sensitive data but entire digital identities – ensuring clients maintain control over their legacy, their public image, and their Google footprint.

Digital Armor for the Ultra-Visible

High-profile individuals don’t just need public relations – they need precision digital control. One deepfake, misquote, or misinformation campaign can derail a lifetime of credibility.

Evrima Chicago offers “reputation sovereignty” by managing Knowledge Panels, Wikipedia entries, and search visibility – well before crises emerge.

Whether it’s a bestselling author, a reclusive investor, or a national figure preparing for confirmation hearings, Evrima’s team ensures the digital battlefield is secured in advance.

Journalism Without Strings: The Evrima Newsroom Model

Unlike most PR firms, Evrima Chicago operates a bias-free, ad-free newsroom. This editorial independence ensures that clients are featured in credible, citation-ready content – no pay-to-play gimmicks, no vanity press.

Their publishing model delivers real authority. With data-backed storytelling and syndication-ready releases, policy influencers and public figures can shape their digital narrative proactively, not reactively.

The Evrima Ethos: Serve the Person, Secure the Legacy

Evrima Chicago isn’t just building technology – it’s building trust in an era where both are in short supply. From octogenarian activists to billionaires in the twilight of their careers, the firm delivers services designed for an aging digital elite.

This is not public relations as usual.
This is cyber guardianship.
This is reputation sovereignty.
This is the future of digital dignity.

Glossary

Assistive Technology (AT): Tools that help individuals with disabilities or age-related limitations live independently – such as screen readers, VR mobility simulations, and adaptive input devices.

A11y: A numeronym for “accessibility” (A + 11 letters + Y), emphasizing inclusive design for users of all ages and abilities.

UHNW: Ultra-high-net-worth individuals with over $30 million in assets, who frequently face heightened cybersecurity and reputational risks.

At Evrima Chicago, the mission is simple but essential:

“A safer, more inclusive digital world – one elder, one executive, one encrypted connection at a time.”

Who is Waa Say?

Waa Say is the caffeinated compass of the Evrima Chicago newsroom – its Editor-in-Chief, chief mischief-maker, and occasional fire extinguisher when headlines get too hot to handle. With a pen sharper than a Senate filibuster and a filing cabinet full of Post-it provocations, Waa Say doesn’t just write stories – he orchestrates editorial ambushes on mediocrity. Working closely with Chicago Bureau Chief Mr. Ovais Riaz, he steers coverage with a blend of literary flair and old-school newsroom grit.

In an America where politics feels like reality TV with fewer writers and worse wardrobe choices, Waa Say finds clarity in chaos. He’s the guy who’ll quote both Baldwin and Bugs Bunny before a deadline, reminding readers that truth needs teeth-and sometimes a punchline.

Disclaimer

This article was produced by Evrima Chicago LLC for editorial and informational purposes. The views expressed are drawn from cited sources and do not necessarily reflect the positions of any government, agency, or client. For inquiries, contact pr@evrimachicago.com or waasay@evrimachicago.com.

Sources and Citations

Source	Details
AARP (2021)	Technology Trends Among Older Adults – AARP Research Report
European Commission (2018)	European Silver Economy Study
Evrima Chicago (n.d.-a)	Internal Policy & Accessibility Framework – www.evrimachicago.com
Evrima Chicago (n.d.-b)	Newswire & Syndication Overview – www.evrimachicago.com/newswire
FBI (2023)	Internet Crime Report – Federal Bureau of Investigation
National Institute on Aging (n.d.)	Assistive Technology for Older Adults – U.S. Department of Health and Human Services
WHO (n.d.)	Ageing and Health – World Health Organization
World Economic Forum (2023)	Global Cybersecurity Outlook Report

SOURCE: Evrima Chicago LLC.

View the original press release on ACCESS Newswire

HOUSTON, TX / ACCESS Newswire / June 18, 2025 / Epique Realty, one of the fastest-growing brokerages in the nation, has announced a groundbreaking partnership with Courted, the award-winning agent attraction and retention platform. This revolutionary alliance will provide every Epique agent with full access to Courted’s advanced technology – an unprecedented move that sets a new standard for agent empowerment across the real estate industry.

At a time when Epique Realty is rapidly expanding across the country and changing lives with its agent-first philosophy, this partnership supercharges that mission with best-in-class AI-powered recruiting intelligence, personalized retention insights, and market visibility tools once only reserved for executive leadership. Now, all Epique agents – no matter where they are – will have the same level of market data and strategic insight once limited to the top floor.

“We’re excited to partner with Epique Realty, a company that shares our vision for agent empowerment through smart, data-driven solutions,” said Sean Soderstrom, Co-Founder and CEO of Courted. “Epique’s decision to provide Courted to all agents is a forward-thinking investment in agent success, scalability, and a bold competitive play. This partnership is a testament to Epique’s pursuit of innovation – not just to drive immediate results but to create a platform for long-term growth through agent attraction.”

Soderstrom added: “Our ability to drive growth for a cloud-based brokerage by equipping its agents and teams with powerful tools is made possible by the rapidly expanding functionality of the Courted platform. We started as an AI-native company, and that foundation has proven essential as we harness today’s pace of innovation across our structured and proprietary data sets.”

This partnership reflects Epique’s relentless commitment to creating an unmatched experience for its agents – delivering extraordinary value, powerful technology, and unlimited opportunities at no cost to them. Through Courted, Epique agents will gain predictive insights into local market movements, AI-powered outreach tools, and visibility into agent migration trends – making it easier than ever to build and grow high-performing teams.

Joshua Miller, CEO and Co-Founder of Epique Realty, shared: “Our partnership with Courted isn’t just a tech integration, it’s a massive leap forward in our mission to revolutionize real estate from the inside out. We believe agents deserve every advantage to succeed, and Courted gives our people the data, insight, and reach to grow smarter and faster. This is what happens when innovation meets intention.”

Janice Delcid, CFO and Co-Founder of Epique Realty, added: “At Epique, we invest in people first. That’s what makes this partnership so aligned with our values. Courted amplifies our ability to support agents with tools that build sustainable businesses, create deeper connections, and foster long-term growth. It’s not just a win for our agents – it’s a win for the communities they serve.”

Christopher Miller, COO and Co-Founder of Epique Realty, stated: “This is more than access to data – it’s an agent’s gateway to transformation. With Courted, our agents can identify, connect, and collaborate like never before. It’s a strategic advantage that levels the playing field and raises the bar. We’re building something profoundly different at Epique – and this is a bold step forward.”

This move makes Epique the first real estate company to deploy Courted at scale for its entire agent community – solidifying its role as a trailblazer in AI innovation, agent growth, and culture-first leadership. Together, Epique and Courted are rewriting the rules of real estate – equipping agents with the power to own their future, grow their businesses, and attract like-minded leaders into a thriving community.

This is the future. And at Epique, the future is already here.

About Courted
Courted is the leading recruiting and retention platform for residential real estate brokerages. Designed to help companies grow smarter, Courted uses proprietary predictive analytics and production data to help brokerages identify, engage, and convert top agent talent – and retain their best performers.

Learn more at www.courted.io/start

About Epique

Epique Realty is a trailblazing, agent-first real estate brokerage committed to empowering its agents through a comprehensive suite of free resources and benefits including extraordinary support, award-winning AI technology, and a culture of radical generosity that fuels agent success. By questioning industry norms and putting agents at the center of its universe, Epique is not just transforming the real estate market – it is defining the future. #BeEpique

Learn more at www.epiquerealty.com

Barbara Simpson | PR and Communications
281-773-7842 | Barbara@EpiqueRealty.com

https://www.instagram.com/epiquerealty/
https://www.facebook.com/epiquerealty
https://www.linkedin.com/company/epique-realty/mycompany/
https://www.youtube.com/@epiquerealty

SOURCE: Epique Realty

View the original press release on ACCESS Newswire

Acclaimed entrepreneur and tech trailblazer join the team shaping Canada’s leading innovation events

TORONTO, ON / ACCESS Newswire / June 18, 2025 / Elevate, the non-profit organization behind Canada’s most influential tech and innovation festival, is pleased to announce that Arlene Dickinson and Amber Mac have joined its Advisory Board. Dickinson, Founder of District Ventures Capital and a longtime Dragon, is one of Canada’s most respected entrepreneurs. Mac is a tech and media trailblazer, President of award-winning content development agency AmberMac Media.

Elevate CEO and Co-Founder, Lisa Zarzenczny, welcomes these powerhouse leaders as the organization gears up for its seventh annual Elevate Festival (October 7-9, 2025) in Toronto, which will bring together over 250 speakers and 10,000 attendees from across the global tech community. This year’s Main Stage will touch on applied AI to revolutionize customer experiences, autonomous transportation, and personalized health insights, among many other content themes and program offerings. The Festival has a track record of catalyzing hundreds of thousands of dollars in startup investments and leads in the industry in gender diversity. The organization also hosts CIX Summit and year-round Elevate Innovation programs to help Canadian founders build their businesses.

“I’ve spent my life in venture capital and marketing helping entrepreneurs and organizations grow their businesses and their dreams,” said Arlene Dickinson. “It’s never been more important to support Canadian innovation and invest in our collective future. I’m happy to join Elevate to help advance this mission.”

“Elevate has made a significant impact in growing the local innovation ecosystem, and I’m proud to help them accelerate their next chapter,” said Amber Mac. “Canada is emerging as an AI superpower but we need to work together to achieve a better digital future for all.”

Dickinson and Mac join current board members:

• Christopher Wein, Chief Operating Officer, Equiton Development;

• Debbie Gamble, Group Head, Strategy & Marketing, Interac;

• Gianluca Cairo, VP, Operations & Strategy, Ceridian;

• James Hicks, President & CEO, Moneris;

• Lisa Zarzeczny, Co-Founder & CEO, Elevate;

• Rizwan Khalfan, EVP, Canadian Personal Banking Digital, TD;

• Salim Teja, Partner, Radical Ventures.

About Arlene Dickinson

Arlene Dickinson is the Founder and General Partner of District Ventures Capital, a VC fund investing in innovative companies that are transforming the way we live and eat. She is widely recognized for her role as a Venture Capitalist on Dragons’ Den, where she has starred for over 17 seasons, and is a three-time bestselling author.

About Amber Mac

Amber Mac is President of AmberMac Media, Inc., an award-winning content development agency, and host of The AmberMac Show podcast on SiriusXM. She was named one of DMZ’s Women of the Year in 2024 and is a bestselling author of multiple books including the Amazon bestseller, Outsmarting Your Kids Online.

About Elevate

Elevate is a Canadian non-profit that unites world-class innovators to catalyze transformation in the Canadian tech ecosystem. Through year-round programs and events, including the annual Elevate Festival and CIX Summit, Elevate shines a spotlight on Canadian innovation, facilitates global connections with startups and investors, and inspires Canadians to embrace a go-for-gold mentality to help shape the future of the Canadian innovation economy.

Media Contact:
Amanda Connon-Unda
Senior Director of Marketing, Elevate
amanda@elevate.ca

SOURCE: Elevate

View the original press release on ACCESS Newswire

GoodData recognized by Gartner® for ability to execute and completeness of vision.

SAN FRANCISCO, CA / ACCESS Newswire / June 18, 2025 / GoodData, the AI-native analytics platform, today announced its inclusion in the 2025 Gartner® Magic Quadrant™ for Analytics and Business Intelligence Platforms. Recognized as a Niche Player, GoodData was acknowledged for its ability to execute and completeness of vision.

At the core of GoodData’s platform is its composability strategy, powered by open source technology, multi-tenancy framework, and an open semantic layer, giving data teams the ability to define metrics once and reuse them across every dashboard, application, or tool in the enterprise. This ensures consistent, governed insights at scale while aligning analytics with business logic and objectives.

“GoodData was built for a world where analytics isn’t a nice-to-have. It is a critical part of the enterprise data landscape, and we believe that our inclusion in the Gartner Magic Quadrant is a testament to the demand for interoperable analytics platforms that treat analytics as code and fit seamlessly into the modern DevOps and product development lifecycle.”

Roman Stanek, CEO and Founder of GoodData.

With its analytics-as-code approach, GoodData enables development teams to build and extend data experiences like any other software component. This empowers teams to automate development with CI/CD pipelines, fully customize the user experience through APIs and embedded components, and ensure trust in the data through automated testing and version control.

Additionally, GoodData’s commitment to interoperability sets it apart. Native features like FlexConnect and metadata ingestion from third-party BI tools allow teams to unify data across silos and ecosystems without duplicating or moving data. The platform’s zero-copy architecture enhances performance while maintaining data integrity and governance.

“GoodData’s flexibility to integrate into any backend setup has proven to provide maximum flexibility for our engineering needs.”

VP, Product in the Banking sector; from Gartner® Peer Insights™ review

“The future of BI is not in monolithic dashboards – it’s in flexible, embedded, and governed insights that live where decisions are made. By focusing on analytics-as-code and end-to-end composability, we’re equipping data and product teams with the tools they need to innovate faster and smarter.”

Ryan Dolley, VP of Product Strategy at GoodData

In our opinion, GoodData’s position in the Magic Quadrant underscores a market shift toward developer-centric analytics platforms that seamlessly integrate into today’s complex data stacks and product environments. Read the full Gartner® Magic Quadrant™ report to see a complete analysis of GoodData’s strengths and cautions.

---

GARTNER is a registered trademark and service mark of Gartner and Magic Quadrant and Peer Insights are a registered trademark, of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.

Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences with the vendors listed on the platform, should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.

Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

---

About GoodData

GoodData is the AI-native analytics platform built for speed, scale, and trust, helping companies deliver real-time insights – embedded, branded, and everywhere your users need them.

Founded in 2007, and with offices in both the U.S. and Europe, GoodData serves over 140,000 of the world’s top companies and 3.2 million users, helping them drive meaningful change and maximize the value of their data.

For more information, visit GoodData’s website and follow GoodData on LinkedIn, YouTube, and Medium.

GoodData Contact
press@gooddata.com

©2025, GoodData Corporation. All rights reserved. GoodData and the GoodData logo are registered trademarks of GoodData Corporation in the United States and other jurisdictions. Other names used herein may be trademarks of their respective owners.

SOURCE: GoodData

View the original press release on ACCESS Newswire

Study used cell lines obtained from the Progeria Research Foundation to evaluate Telomir-1’s effects on key drivers of accelerated aging

MIAMI, FLORIDA / ACCESS Newswire / June 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a preclinical-stage biotechnology company focused on reversing biological aging and age-related diseases, today announced compelling new preclinical data showing that its lead candidate, Telomir-1, prevented cellular aging in human progeria cell lines obtained from the Progeria Research Foundation. Progeria, or Hutchinson-Gilford Progeria Syndrome (HGPS), is an ultra-rare pediatric disorder caused by a mutation in the LMNA gene. This mutation results in the production of an abnormal protein called progerin, which drives rapid biological aging in children.

There are an estimated 400-500 known cases worldwide, including fewer than 30 children currently living with the disease in the United States. Symptoms typically begin within the first two years of life and include growth failure, joint stiffness, loss of body fat and hair, and severe cardiovascular disease. Children with progeria have an average life expectancy of just 13 to 15 years, with most dying from heart attacks or strokes at a young age.

The only FDA-approved therapy for progeria, Zokinvy® (lonafarnib), is a farnesyltransferase inhibitor that has been shown to extend lifespan by an average of 4.3 years. However, Zokinvy does not reverse the underlying disease pathology or halt cardiovascular deterioration, which remains the leading cause of death. No approved therapy restores normal cell function or reverses the biological hallmarks of accelerated aging in progeria, highlighting a significant and urgent unmet medical need.

Telomir-1 is designed to regulate intracellular metal ions, reduce oxidative stress, restore mitochondrial function, extend telomere length, reverse muscle loss, and reset age-associated DNA methylation patterns – all of which are critical biological pathways implicated in progeria and broader age-related diseases.

In this study, conducted by Smart Assays, Telomir-1 was tested in cells taken directly from a child with HGPS. These cells were obtained from The Progeria Research Foundation (www.progeriaresearch.org). The study evaluated cell viability, reactive oxygen species (ROS), and intracellular calcium signaling – a marker of mitochondrial dysfunction – under both normal and stress-induced conditions.

Key findings include:

• Improved cell viability: Telomir-1 increased survival in a dose-dependent manner, both under basal conditions and even under stress conditions induced by copper and iron-two metal ions known to accelerate aging by generating oxidative damage and destabilizing DNA and telomeres.

• Reduction of oxidative stress: Progeria cells exhibited abnormally high levels of reactive oxygen species (ROS), a hallmark of cellular aging. Telomir-1 normalized these levels, both under basal conditions and even when ROS was further elevated by toxic metal exposure.

• Restoration of mitochondrial function: Iron-induced calcium overload – a signal of mitochondrial damage and a known feature of HGPS – was significantly reduced with Telomir-1, indicating restored mitochondrial regulation and improved cellular energy balance.

These results demonstrate that Telomir-1 directly addresses the core cellular dysfunctions driving disease features in progeria – not only protecting cells from damage but restoring critical biological functions. The fact that these results were observed in actual patient-derived human cells offers strong early validation of Telomir-1’s therapeutic potential.

“These results provide the strongest evidence to date that Telomir-1 is not only protective but also restorative at the molecular and cellular level,” said Dr. Angel, Chief Scientific Advisor of Telomir. “What’s especially promising is that the improvements we observed directly target the mechanisms known to drive disease progression in progeria – oxidative stress, metal toxicity, and mitochondrial instability. This level of functional rescue in actual patient-derived cells is highly encouraging as we move toward clinical translation. These studies come as further validation of the very promising results obtained previously in both nematode and zebrafish models of adult progeria.”

“These findings deepen our conviction that Telomir-1 can be a first-in-class therapeutic platform for rare aging syndromes and broader age-related diseases,” said Erez Aminov, CEO of Telomir. “By demonstrating the ability to reverse cellular damage in human progeria cells, Telomir-1 represents a potential breakthrough for children who currently have no real options beyond modestly delaying the inevitable. This work also lays the foundation for broader applications in neurodegeneration, metabolic dysfunction, and systemic aging.

The new data also build on previously reported studies in zebrafish and C. elegans nematodes harboring the wrn gene mutation (a model of adult progeria, or Werner syndrome), where Telomir-1 significantly extended lifespan, restored telomere length, reversed muscle degeneration, and normalized molecular age markers.

Telomir is currently finalizing IND-enabling studies for Telomir-1 and plans to engage with the U.S. Food and Drug Administration (FDA) to explore regulatory pathways, including the potential for orphan drug designation. The company is evaluating multiple rare disease indications for initial clinical development.

Cautionary Note Regarding Forward-Looking Statements

This press release, statements of Telomir’s management or advisors related thereto, and the statements contained in the news story linked in this release contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.

Any forward-looking statements in this press release are based on Telomir’s current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir’s programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which are on file with the SEC and available at www.sec.gov. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Helga Moya
info@telomirpharma.com
(786) 396-6723

SOURCE: Telomir Pharmaceuticals, Inc

View the original press release on ACCESS Newswire

SIOUX FALLS, SD / ACCESS Newswire / June 18, 2025 / Avel eCare, a leading provider of telemedicine services, today announced a strategic partnership with Alliant Purchasing, one of the nation’s largest independent Group Purchasing Organizations (GPOs), to bring innovative virtual care solutions to more than 35,000 healthcare provider organizations across the U.S.

Through this partnership, Alliant Purchasing members, including rural and urban hospitals, clinics, and long-term care facilities, will gain preferred pricing and streamlined access to Avel eCare’s full suite of 10 virtual service lines. The services are designed to help address critical healthcare challenges, including clinical staffing shortages, the need to keep care local, and the ongoing demand for high-quality, affordable care across the healthcare continuum.

“We are excited to bring Avel’s expertise and services to our members,” said Kary LeBlanc, COO of Alliant Purchasing. “Avel’s telemedicine solutions offer an important opportunity for our members, particularly those in rural communities, to expand access to care while improving outcomes and addressing staffing challenges. By integrating Avel into our vendor options, Alliant members now have a seamless and cost-effective path to virtual care implementation.”

Under the partnership, Alliant Purchasing members will have preferred access and pricing on Avel’s extensive telemedicine service portfolio:

• Emergency

• Hospitalist

• Pharmacy

• Behavioral Health

• ICU (Critical Care)

• Virtual Nursing

• School Health

• EMS Support

• Senior Care

“This partnership directly supports Avel’s mission of helping healthcare providers-large and small-thrive in today’s challenging environment,” said Doug Duskin, CEO of Avel eCare. “Together, we are empowering providers to meet growing patient needs, improve care quality, and ease the burden on overstretched clinical teams. This is especially vital for rural hospitals, where staffing shortages often threaten the ability to keep care local.”

Avel’s services are backed by more than 30 years of clinical and telemedicine innovation, providing 24/7 access to board-certified specialists and delivering proven results.

About Alliant Purchasing
For more than 30 years, Alliant Purchasing has served a diverse group of healthcare providers nationwide. Originally conceived by a large urban healthcare system to assist small rural hospital partners, Alliant continues its tradition of combining divergent interests to create collective value. Today, Alliant serves more than 230 hospital members and over 35,000 members and leverages more than $84 billion in buying power to simplify the healthcare supply chain and provide transformational value. For more information, visit https://www.alliantpurchasing.com

About Avel eCare
Avel eCare is a national leader in technology enabled clinical services delivered through telemedicine, delivering provider-to-provider virtual care solutions that expand clinical capacity and improve outcomes across the healthcare industry. With more than 30 years of innovation, Avel’s board-certified clinicians’ partner with hospitals, clinics, long-term care facilities, schools, EMS agencies, and correctional health systems nationwide to bring high-quality care to patients when and where it’s needed most. Learn more at: www.avelecare.com

Media Contact:
Jessica Gaikowski
Avel eCare
media@avelecare.com

SOURCE: Avel eCare

View the original press release on ACCESS Newswire

NEW YORK CITY, NY / ACCESS Newswire / June 18, 2025 / Vero Technologies is pleased to announce its participation in the 2025 NIADA Convention & Expo, the premier annual gathering for the independent automobile dealer industry, taking place June 23-26 at the Fontainebleau Las Vegas.

CEO and Co-Founder John Mizzi and VP of Partnerships Jason Bartz will represent the company at the convention. Together, they’ll engage with specialty finance companies, auctions, and other lenders who provide critical financing solutions to independent dealers nationwide.

The NIADA Convention & Expo brings together thousands of independent automobile dealers and industry partners for four days of education, networking, and innovation. As the largest event in the independent auto industry, it provides an unparalleled platform for meaningful connections between dealers and the financial partners who support their businesses.

“Independent dealers are a critical part of the retail automotive ecosystem, and the lenders behind them often work with aging systems that create more friction than value,” said John Mizzi, CEO of Vero Technologies. “We’re looking forward to hearing firsthand how these providers are thinking about scale, compliance, and risk, and sharing how a modular approach like VeroOS can help streamline their day-to-day without disrupting what already works.”

Vero’s attendance at NIADA underscores the company’s focus on empowering lenders who serve the independent auto market. The convention will provide opportunities to explore how Vero’s technology platform can help these financial partners streamline their operations, reduce costs, and deliver superior service to their dealer customers.

About NIADA

The National Independent Automobile Dealers Association (NIADA) is among the nation’s largest trade associations, representing the used motor vehicle industry comprised of over 40,000 licensed dealers. Since 1946, NIADA has represented the voice and interests of used car dealers at the federal level in Washington D.C. Learn more at www.niada.com.

About Vero Technologies

Vero Technologies is a leading financial technology platform for asset finance, providing end-to-end solutions for wholesale finance, trade finance, equipment finance, and title management. Vero’s modular platform enables lenders to streamline loan servicing, risk monitoring, and operational workflows – enhancing efficiency while reducing costs.

To learn more, visit: www.vero-technologies.com.

Contact: Jason Bartz, info@vero-technologies.com, 404-383-7048

SOURCE: Vero Finance Technologies

View the original press release on ACCESS Newswire

RALEIGH, NC / ACCESS Newswire / June 18, 2025 / iAccess Alpha’s Virtual Best Ideas Summer Investment Conference will take place on June 24-25, 2025, bringing together top micro-cap companies and investors for two days of high-quality insights and investing opportunities.

The event begins on Tuesday, June 24, 2025, with a series of live-streamed company presentations, beginning at 9:00 AM ET. The following day, Wednesday, June 25, will be dedicated to 1×1 meetings between presenting companies and investors, starting at 8:00 AM ET.

How to Attend:

Investors and industry professionals can register to watch the presentations and request 1×1 meetings by visiting the official event website: Register Here

Conference Schedule – June 24, 2025 (All Times ET):

Time	Company	Ticker	Webcast Link
9:00am	Inuvo Inc.	NYSE/AMEX:INUV	View Presentation
9:30am	Digi Power X Inc.	NASDAQ:DGXX /TSXV:DGX	View Presentation
10:00am	Surgepays Inc.	NASDAQ:SURG	View Presentation
10:30am	Coya Therapeutics Inc.	NASDAQ:COYA	View Presentation
11:00am	MIND Technoloy Inc.	NASDAQ:MIND	View Presentation
11:30am	Data IO Corp.	NASDAQ:DAIO	View Presentation
12:00pm	TBA	TBA	TBA
12:30pm	Upexi Inc.	NASDAQ:UPXI	View Presentation
1:00pm	DocGo Inc.	NASDAQ:DCGO	View Presentation
1:30pm	SKYX Platforms Corp.	NASDAQ:SKYX	View Presentation
2:00pm	HeartBeam Inc.	NASDAQ:BEAT	View Presentation
2:30pm	Heritage Global Inc.	NASDAQ:HGBL	View Presentation
3:00pm	Mobilicom Ltd.	NASDAQ:MOB	View Presentation
3:30pm	Envela Corp.	NYSE/AMEX:ELA	View Presentation

About iAccess Alpha’s Virtual Best Ideas Investment Conferences

iAccess Alpha hosts four virtual investment conferences annually (March, June, September, and December), showcasing high-potential small and micro-cap investment opportunities. The conferences feature live company presentations on Day 1, followed by exclusive 1×1 investor meetings on Day 2. Since 2019, iAccess Alpha has co-organized leading microcap-focused events, connecting top-tier investors with high-potential companies.

For more information, contact:
info@iaccessalpha.com
www.iaccessalpha.com

SOURCE: iAccess Alpha

View the original press release on ACCESS Newswire

MIAMI, FL / ACCESS Newswire / June 18, 2025 / MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced that the first manuscript describing its lead drug candidate Ketamir-2, currently being evaluated in an ongoing Phase 1 clinical trial for neuropathic pain, has been accepted for publication in the peer-reviewed journal Frontiers in Pharmacology.

The article, titled “KETAMIR-2, A NEW MOLECULAR ENTITY AND NOVEL KETAMINE ANALOG,” authored by Itzchak Angel, Ph.D., MIRA’s Chief Scientific Advisor, highlights Ketamir-2’s pharmacological differentiation from ketamine and its potential as a next-generation CNS therapeutic.

Peer Review Validates Differentiated Pharmacology and Safety

Acceptance into Frontiers in Pharmacology provides external scientific validation by independent experts, underscoring the rigor and credibility of MIRA’s research. The publication confirms that Ketamir-2 was specifically engineered to overcome limitations associated with ketamine-such as poor oral bioavailability, dissociative side effects, and non-specific receptor binding.

Key Highlights from the Publication:

• Highly Selective, Cleaner Mechanism: Ketamir-2 is a low-affinity NMDA receptor antagonist that selectively targets the NMDA PCP site. Unlike ketamine, Ketamir-2 showed no significant interaction with over 40 other receptors, transporters, or ion channel targets-including dopamine, opioid, serotonin, and monoaminergic systems-highlighting its clean pharmacological profile and reduced off-target effects.

• No Hyperlocomotion, Even at High Doses: In contrast to ketamine, Ketamir-2 did not induce hyperlocomotion in preclinical models-a behavior associated with agitation and schizophrenia-like symptoms-suggesting a favorable neurobehavioral safety profile.

• Demonstrated Antidepressant and Anxiolytic Activity: In validated behavioral models (Open Field Test, Elevated Plus Maze, Forced Swim Test), Ketamir-2 demonstrated clear anxiolytic and antidepressant-like effects. Ketamine, used as a control, either showed no benefit or limited effect in most tests.

• Oral Delivery with Efficient Brain Penetration: All studies were conducted via the oral route. Ketamir-2 was shown to cross the blood-brain barrier and is not a substrate for P-glycoprotein, which often limits oral drug delivery to the brain. This may explain Ketamir-2’s ability to maintain CNS activity despite its lower NMDA receptor affinity.

“We are honored to see our foundational research on Ketamir-2 published in a high-impact scientific journal,” said Erez Aminov, CEO of MIRA. “This milestone adds meaningful scientific credibility and supports our confidence in Ketamir-2’s differentiated mechanism, favorable safety profile, and broad clinical potential.”

“This peer-reviewed publication provides clear validation of the differentiated pharmacological profile of Ketamir-2,” added Dr. Itzchak Angel, Chief Scientific Advisor. “Its clean pharmacological profile and safety make it a compelling next-generation alternative to ketamine.”

Clinical and Corporate Updates

MIRA also announced that its Phase 1 trial of Ketamir-2 is progressing as planned, with no safety concerns reported to date and dose escalation advancing. The Company expects to initiate a Phase 2a clinical trial in neuropathic pain by year-end 2025, pending regulatory clearance.

In addition, the Company is preparing new scientific data submissions and presentations to further support Ketamir-2’s clinical development and potential across CNS-related conditions.

MIRA also reaffirmed that the acquisition of SKNY Pharmaceuticals, which includes a first-in-class oral CB1/CB2 inverse agonist for obesity and smoking cessation (SKNY-1), is progressing on track. The Company has submitted the required regulatory filings for the merger to the U.S. Securities and Exchange Commission (SEC).

The publication will be available upon release at: www.frontiersin.org/journals/pharmacology

Cautionary Note Regarding Forward-Looking Statements

This press release and the statements of MIRA’s management related thereto contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA’s control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA’s potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA’s programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and other SEC filings, which are on file with the SEC at www.sec.gov and MIRA’s website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Helga Moya
info@mirapharma.com
(786) 432-9792

SOURCE: MIRA Pharmaceuticals

View the original press release on ACCESS Newswire

ROSH HA‘AYIN, IL / ACCESS Newswire / June 18, 2025 / Brenmiller Energy Ltd. (“Brenmiller”, “Brenmiller Energy” or the “Company”) (NASDAQ:BNRG), a leading global provider of Thermal Energy Storage (“TES”) solutions for industrial and utility customers, today issued a letter from its Chief Executive Officer, Avi Brenmiller.

To Our Shareholders,

As previously announced, today at the close of trading on the Nasdaq Capital Market, Brenmiller Energy will implement a reverse share split-a strategic and proactive decision made to protect and preserve shareholder value as we approach a critical period of execution on our business objectives.

This decision followed extensive internal consideration about the timing and impact of a reverse share split. Ultimately, we determined that the best course of action was to be decisive today, which will allow us to remain focused on what matters most in the days ahead: delivering on our milestones.

The value that Brenmiller Energy has built is evident:

• More than a decade of TES innovation and $118 million in investments have led to deployments across Europe, the U.S., and the Middle East

• Commissioning and building over 100 MWh of projects

• A $500 million pipeline of commercial opportunities

• 4GWh of manufacturing capacity

Let us be clear: a reverse split changes the number of shares outstanding, but it does not impact your ownership.

All shareholders-including insiders-are impacted equally by this reverse split. That’s not incidental. It’s intentional. We are all in this together. Our Company’s founders and management, including myself, continue to have significant holdings in Brenmiller Energy. Investors can be assured that all of our interests are aligned.

As we are aiming to move towards key implementation milestones for commercial deployment in the near-term, with funding commitments for projects within our existing portfolio, and strategic collaborations-we believe that these future achievements will translate into tangible value for shareholders.

We’re not waiting for the market to understand what we’ve built. We are aiming to make it impossible to ignore.

As we’ve shared throughout 2025, we believe that Brenmiller Energy has entered a new phase-one defined by acceleration. Our recent progress with TES projects including Tempo Beverages in Israel and SolWinHy in Spain makes that clear: we believe we are on the verge of a breakout moment with a robust global commercial pipeline and technology that’s already proven in the field.

The result? Real operating momentum that we believe will spark interest in our technology-and a reappraisal of the value it truly deserves.

We thank you for standing with us, and we invite you to stay close. We believe that the weeks ahead won’t just validate our vision-they’ll define it.

Sincerely,

Avi Brenmiller
CEO, Brenmiller Energy Ltd.

About Brenmiller Energy Ltd.

Brenmiller Energy helps energy-intensive industries and power producers end their reliance on fossil fuel boilers. Brenmiller’s patented bGen™ ZERO thermal battery is a modular and scalable energy storage system that turns renewable electricity into zero-emission heat. It charges using low-cost renewable electricity and discharges a continuous supply of heat on demand and according to its customers’ needs. The most experienced thermal battery developer on the market, Brenmiller operates the world’s only gigafactory for thermal battery production and is trusted by leading multinational energy companies. For more information visit the Company’s website at https://bren-energy.com/ and follow the company on X and LinkedIn.

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements when it discusses: expected near-term milestones; the timing for implementing a reverse share split; its protecting and preserving shareholder value as the Company approaches a critical period of execution its business objectives;; the Company’s future commercial deployment milestones, funding commitments for projects within its existing portfolio, and strategic collaborations and that such future achievements will translate into tangible value for shareholders; future interest in the Company’s technology and a reappraisal of its value; and the Company’s $500 million pipeline of commercial opportunities. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. Factors that may affect the Company’s results include, but are not limited to: the Company’s planned level of revenues and capital expenditures; risks associated with the adequacy of existing cash resources; the demand for and market acceptance of our products; impact of competitive products and prices; product development, commercialization or technological difficulties; the success or failure of negotiations; trade, legal, social and economic risks; and political, economic and military instability in the Middle East, specifically in Israel. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (“SEC”) on March 4, 2025, which is available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact: investors@bren-energy.com

SOURCE: Brenmiller Energy

View the original press release on ACCESS Newswire